Theranos’ denouement: Holmes and Balwani lose their appeals

It’s been two years since Theranos was in the news. In April 2023, both Elizabeth Holmes and Ramesh ‘Sunny’ Balwani started serving their lengthy sentences for multiple charges of fraud (11 years, 3 months and 12 years, 9 months respectively, generally reduced to 85% of sentence). Last week, the three judges of the US Court of Appeals for the Ninth Circuit in San Francisco ruled to uphold both trials on investor fraud and the award of $452 million in restitution. The original verdicts were made in separate trials in the US District Court for the Northern District of California by Judge Edward Davila, but the appeals were considered together. [TTA 12 June 2024]

Neither appeal of the separate trials proved that any errors were significant enough, nor any testimony excluded, that would provide grounds to overturn the verdict.

The key issues centered on legal errors made by the District Court in allowing certain witnesses’ testimony to veer into ‘expert territory’, which is an error, but that “any error was harmless”. For instance, both defenses concentrated on Kingshuk Das, MD, the final Theranos lab director who worked there March 2016 to June 2018 and voided two years of Edison Lab tests. He testified about his experience at Theranos (fact witness) but in court was allowed to express his opinion as a scientist though he was not qualified by the court as an ‘expert witness’. That is a separate procedure that involves a special qualifications hearing (Daubert hearing) that did not take place with Dr. Das. The appeals panel found that Dr. Das should have been qualified as a expert witness and would have easily done so. Not doing so was an error that was not challenged by Holmes’ team at the time. But the court’s error was harmless. Dr. Das’ testimony on the Edison devices’ reliability and accuracy was supported by other testimony. The testimony regarding the device was one of many other misrepresentations made to investors that the jury had to review. 

Another issue was the CMS report on the labs, issued in January 2016 after much of the deception had already taken place. Holmes’ appeal team argued it should have been excluded as misleading to the jury. It was admitted into evidence as relevant to Holmes’ state of mind, intent, and knowledge about the labs’ conditions. The District Court did not “abuse its discretion” in permitting it for that limited purpose.

Holmes’ team also challenged the exclusion of statements from Sunny Balwani about “owning” the Theranos financial model.

Regarding restitution, the conclusion in the ruling summary was direct: “The panel concluded that any error was harmless because the district court’s factual findings compel the conclusion that the victims’ actual losses were equal to the total amount of their investments.”

The very tough decision was written by Judge Jacqueline H. Nguyen. Her fellow judges were Mary M. Schroeder and Ryan D. Nelson. The decision PDF is here. (It seems quite readable, but was not fully read by this Editor.)

Their chances for further appeal, either in the Ninth Circuit with a larger panel or by the US Supreme Court, as “very unlikely” for the first and “almost inconceivable” for the second, according to Stanford Law professor Robert Weisberg, quoted in the Mercury News.

This Editor recommends a review of the Reddit thread by mattschwink, “Annotating the 9th Circuit review of Holmes appeal”, which was (again) of great assistance in summarizing the appeal issues. He also confirmed for me that Sunny Balwani was moved from the limited facilities at Terminal Island FCI to Lompoc FCI, north of Santa Barbara and a stone’s throw from Vandenberg Space Force Base. Thank you, Matt, again! Press coverage has been minimal: Mercury News, AP, BBC

Immediately preceding the 9th Circuit Court’s decision was a People cover puff piece on Elizabeth Holmes. You may be able to read it all the way through without being amazed at her manipulation and lack of contrition on defrauding investors and patients. It doth make much of her claims that she was sexually abused not only at a college party but also in her years with Sunny Balwani, for which she is in therapy there. She is continuing to research and write patents for new healthcare inventions, presumably between law clerking, advocacy, teaching French, and weekend family visits. The Bryan FCI does not, even in her description, sound like ‘It’s Been Hell and Torture’. (Perhaps she’s seeking a Federal pardon?) More than likely, she will be enjoying the facilities and the visits until April 2032. And then there is the $452 million restitution to somehow scrape up.

No “equal time” exclusive interviews with Sunny Balwani, of course.

It strikes this Editor that, in the words that Orson Welles wrote for his character and that of Marlene Dietrich in ‘Touch of Evil’ that both Holmes’ and Balwani’s futures ‘are all used up’. That is, they will emerge from their respective prisons and live on, but as to any role in medical research, the parade will have long passed them by.

Postscript: The Mercury News published a rather anodyne interview with one of her prosecutors, John Bostic, who is now in private practice as a partner with Cooley in the Bay Area. It’s brief but interesting as to why he was chosen–he was a molecular biology major in college–which helped him to understand the technical aspects of Theranos and make them understandable to judge and jury. The strongest evidence against her? “There was evidence that Holmes knew some things that she was saying were not true, and there was also some evidence of document altering that I think was very easy for the jury to understand.” The one notable takeaway was that Silicon Valley and technology companies shouldn’t ‘fake it till they make it’, which is a lesson they’ve already learned.

Breaking: 23andMe sale bids slide from $2.53 per share to $0.41 to none in 11 days, as board rejects CEO’s offer

23andMe’s future growing dimmer by the day. Last week before Friday, 23andMe seemed to have a fighting chance. The 20 February Schedule 13D filing proposed a take-private offer for $2.53 per share, or $74.7 million, a small premium above their Nasdaq CM trading price, with CEO and controlling shareholder Anne Wojcicki joined by investor New Mountain Capital (NMC) [TTA 27 Feb]. Evidently that offer went sideways before the board of directors’ Special Committee could even consider it. By Friday 28 February, a week later, New Mountain withdrew from the acquisition bid for unspecified reasons. On Sunday 2 March, Ms. Wojcicki offered instead to the board her non-binding all cash bid of $0.41, or about $12 million. This would acquire the current outstanding shares not owned by Ms. Wojcicki (or not rolled over by current shareholders).  Amended Schedule 13D 

It took about “24 little hours” for the 23andMe board and their advisers to unanimously reject that offer, stating that at $0.41, it represented an 84% decrease to the prior $2.53 offer made with New Mountain Capital. Release.  It is one cent above Anne Wojcicki’s offer made back on 31 July 2024, which matched the price of the shares at that time. No one involved had any comments. (Share price today: $1.37)

So the genetic data/testing/telemedicine company returns to Square Zero. One can only speculate why NMC withdrew so quickly, on what they saw after a bid that made them run, not walk, to the exit. One wonders how Anne Wojcicki would offer not only a misfire of a bid, but also counter with a ridiculously low bid that she had to know would be rejected. Then again, one wonders what the board’s options really are, given the parlous state of their cash reserves. Will this be the second board that throws up their six hands and resigns? CNBC, Business Insider

Breaking: Sycamore Partners’ $10B deal for Walgreens may close this week–reports (Updated for debt financing details)–Sale confirmed on Thursday

All that ‘deck clearing’ could be leading to a ‘deal deal’. Late Monday reports in both The Wall Street Journal and Bloomberg News (both paywalled) confirmed last Thursday’s and CNBC’s report the week prior [TTA 27 Feb, 19 Feb] that Sycamore Partners and Walgreens Boots Alliance were getting verrrry close to a deal for WBA. The numbers: $11.30 a share to $11.40 a share, cash, or about $10 billion. Today’s price for WBA shares ticked up to $11/share, giving it a market cap of about $9 billion.

The deal, if on, could be announced as early as this coming Thursday.

As Thursday’s reports intimated, the Sycamore plan would 

  1. Take Walgreens private on closing
  2. Split WBA into three parts or more. Sycamore would keep the US retail side, and sell or spin off the rest. 

WBA’s holdings include the Boots chain in the UK, the Boots beauty brands such as No. 7, US drugstore chain Duane Reade, and the rest of US Healthcare: VillageMD, CityMD, Summit Medical, and CareCentrix. Those sources allegedly familiar with the advanced discussions said all of those could be sold or spun off. VillageMD is already on the block. Sycamore had already lined up the financing based on earlier reports.

Mum was the word from both Walgreens and Sycamore; talks even at advanced points can derail in this Perils of Pauline (left above) scenario. Analysts weren’t jumping for joy either. From MarketWatch: “Last week, Deutsche Bank analyst George Hill warned that Walgreens’ stock had run up too high in acquisition anticipation, giving a $9 price target. “The deal strikes us as incredibly complicated and unlikely to be consummated at a premium to the current share price,” Hill said in a note.”

Readers following the WBA story have noticed the “cleanup on aisle 5” activity going on for the past few weeks. The PWNHealth/Everly Health near $1 billion arbitration award against Walgreens for breach of contract was settled for $595 million last week versus appealing [TTA 26 Feb]. Other ‘straws’ were VillageMD/CityMD’s recent settlements with New York State and the Department of Justice [TTA 12 Feb], and the suspending of Walgreens’ stock dividend after 91 years.

It’ll be either on, off, or still being discussed by the end of this week. Crain’s Chicago Business

Update/Breaking: Sycamore is squaring away at least $12 billion of debt financing with HPS Investment Partners and Ares Management Corp. notably vying for the privilege. Citigroup Inc., Goldman Sachs Group Inc., JPMorgan Chase & Co., UBS Group AG and Wells Fargo & Co. are also working on financing proposals, according to Bloomberg News. Different parts of WBA’s business would receive loans, such as HPS leading a $2.5 billion first-lien term loan to specialty pharmacy Shields Health Solutions and a $4.25 billion combination of short term loans and bonds to finance Boots. It’s one large and complex package for Sycamore. For so many specifics to leak out, the deal is likely very near, either end of week or next. Crain’s Chicago Business

Updated Thursday–the Walgreens-Sycamore sale is agreed to. Details to come.